Eagle Asset Management Inc Apellis Pharmaceuticals, Inc. Transaction History

Eagle Asset Management Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$38.07 - $59.71 $1.65 Million - $2.58 Million	-43,280 Reduced 5.12%	802,253 $30.8 Million
Q1 2024 May 09, 2024	BUY	$55.39 - $72.47 $22.1 Million - $29 Million	399,533 Added 89.58%	845,533 $49.7 Million
Q4 2023 Feb 12, 2024	SELL	$37.14 - $64.82 $147,445 - $257,335	-3,970 Reduced 0.88%	446,000 $26.7 Million
Q3 2023 Nov 13, 2023	SELL	$23.65 - $89.22 $22,751 - $85,829	-962 Reduced 0.21%	449,970 $17.1 Million
Q2 2023 Aug 09, 2023	BUY	$76.68 - $93.31 $17 Million - $20.7 Million	221,550 Added 96.59%	450,932 $41.1 Million
Q1 2023 May 08, 2023	BUY	$46.59 - $66.96 $4.35 Million - $6.25 Million	93,268 Added 68.52%	229,382 $15.1 Million
Q4 2022 Feb 14, 2023	SELL	$43.24 - $61.04 $220,653 - $311,487	-5,103 Reduced 3.61%	136,114 $7.04 Million
Q3 2022 Nov 07, 2022	BUY	$44.76 - $69.66 $6.32 Million - $9.84 Million	141,217 New	141,217 $9.65 Million

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Eagle Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Eagle Asset Management Inc with notifications on news.